Literature DB >> 8028480

Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja.

G A MacGibbon1, P A Lawlor, R Bravo, M Dragunow.   

Abstract

Acute administration of the typical neuroleptic haloperidol (HAL, 2 mg/kg) induced the immediate-early gene proteins (IEGPs) c-Fos, Fos-related antigens (FRAs), FosB, JunB, JunD and Krox24 in the striatum and nucleus accumbens of the rat brain. In contrast, acute administration of the atypical antipsychotic drug clozapine (CLOZ, 30 mg/kg) induced only FRAs, JunB and Krox24 IEGPs in the striatum, and c-Fos, FRAs, and Krox24 IEGPs in the nucleus accumbens. c-Jun was not induced by acute administration of HAL or CLOZ in the rat brain. Differential induction of IEGs by HAL and CLOZ was also observed in the lateral septal nucleus and the islands of Calleja complex of the rat brain. These differences in IEG induction by HAL and CLOZ may be related to the different clinical profiles of the two drugs. Specifically, CLOZ induces FRAs in the islands of Calleja and lateral septum and this action may be involved in its therapeutic effects on the negative symptoms of schizophrenia, whereas HAL produces a coordinate induction of Fos and JunB in striatal neurons and this dimer combination may be involved in producing the extrapyramidal side-effects of typical neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028480     DOI: 10.1016/0169-328x(94)90207-0

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  23 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

4.  The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions.

Authors:  M Zivin; L Sprah; D Sket
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 5.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 6.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 7.  Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations.

Authors:  C C Abbott; A Jaramillo; C E Wilcox; D A Hamilton
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat.

Authors:  Matthew L MacDonald; Molly E Eaton; Joshua T Dudman; Christine Konradi
Journal:  Biol Psychiatry       Date:  2005-05-01       Impact factor: 13.382

9.  c-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat.

Authors:  C Zhao; M Li
Journal:  Neuroscience       Date:  2010-01-22       Impact factor: 3.590

10.  Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.

Authors:  Kwang H Choi; Brandon W Higgs; Serge Weis; Jonathan Song; Ida C Llenos; Jeannette R Dulay; Robert H Yolken; Maree J Webster
Journal:  BMC Psychiatry       Date:  2009-09-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.